References supporting Vico’s RNA modulating therapeutics
As a friend of Rare Disease Day and to show our support in their continuous quest to raise awareness amongst the general public and decision-makers about rare diseases and their...
European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia
Leiden, The Netherlands, 10 February 2021 - Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
Dutch Vico Therapeutics strengthens leadership team with the appointment of Rupert Sandbrink as Chief Medical Officer and Anders Hinsby as Independent Director
Sandbrink, M.D., Ph.D. is a highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Topas, Bayer and Schering. Hinsby, Ph.D. is a seasoned life science entrepreneur and a co-founder and former...
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...
https://pubmed.ncbi.nlm.nih.gov/31429628/ (Not open access)